



PRESS RELEASE

Date 3 April 2017
Contact Investor Relations: Felix Burkhard, CFO, Galenica Group
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group
Subject IPO Galenica Santé: Galenica announces narrowed price range

IPO Galenica Santé: Galenica announces narrowed price range and upsizing of the IPO

The Galenica Group today announced a narrowed price range of CHF 37.00 to CHF 39.00 per share (before CHF 31.00 to CHF 39.00), implying a total market capitalisation of Galenica Santé of approximately CHF 1,850 million to CHF 1,950 million.

Due to strong demand from a broad range of investors, Galenica Group has decided to upsize the base offering by 4,891,300 shares and the over-allotment option by 733,700 shares, respectively. The upsized IPO consists of 42,391,300 ordinary registered shares and an upsized over-allotment option of up to 6,358,700 shares in total.

Assumed that the over-allotment option is exercised in full, the free float of Galenica Santé is now expected to amount to 97.5% of the shares (about 85% before exercise of the over-allotment option). After the listing and assuming the over-allotment option is exercised in full, Galenica Group will not own any shares in Galenica Santé going forward.

The remaining shares, amounting to 2.5% of the share capital of Galenica Santé, are reserved for the exchange of Galenica Group shares into Galenica Santé shares for eligible employees of Galenica Santé.

The bookbuilding period has been shortened by one day and will last until 5 April 2017 at 12:00 noon CEST for retail and private banking orders and 18:00 CEST for institutional investors, respectively. The first day of trading remains Friday, 7 April 2017.

Any investment decision involves risks and must be based on the offering memorandum, which can be obtained from Credit Suisse AG, Zurich, Switzerland (email: equity.prospectus@credit-suisse.com) and from UBS AG, Zurich, Switzerland (telephone number: +41 44 239 47 03; fax number: +41 44 239 69 14; email: swiss-prospectus@ubs.com).

For further information, please contact:

Media Relations:

Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Felix Burkhard, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646). Additional information concerning the Galenica Group can be found at www.galenica.com.

Galenica Ltd.
P.O. Box · Untermattweg 8 · CH-3001 Bern
Phone +41 58 852 85 17 · Fax +41 58 852 85 58
media@galenica.com · www.galenica.com

Date 3 April 2017
Page 2/2
Subject IPO Galenica Santé: Galenica announces narrowed price range

Disclaimer

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. A decision to invest in securities of Galenica Santé AG (the "Company") should be based exclusively on the issue and listing prospectus to be published by the Company for such purpose.

This document and the information contained herein are for information purposes only and do not constitute a prospectus or an offer to sell, or a solicitation of an offer to buy, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or pursuant to an available exemption from registration under the Securities Act. Neither Galenica Santé AG (the "Company") nor its shareholder intends to register any securities referred to herein in the United States.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is being communicated only to (i) persons who are outside the U.K.; (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (iii) high net worth companies, unincorporated associations and other bodies who fall within article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This document should not be published, reproduced, distributed or otherwise made available, in whole or in part, to any other person without the prior consent of the Company.

Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an "EEA Member State") that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the "Prospectus Directive") is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.

The Joint Bookrunners and Co-Lead Managers are acting exclusively for the Company and no-one else in connection with the Offering. They will not regard any other person as their respective clients in relation to the Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Offering, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

This document contains forward-looking statements. These statements are based on the current views, expectations, assumptions and information of the management of the Company. Forward-looking statements should not be construed as a promise of future results and developments and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those described in such statements due to a number of factors. The Company does not assume any obligations to update any forward-looking statements.